This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Communicable diseases, Subject name: Social & Preventive Medicine
[{'content': 'Raltegravir belongs to \nSelect and explain. \nA. NIs, B. NNIs, C. INSTIs, D. CCR5 antagonist', 'role': 'user'}, {'content': 'Answer: C \nExplanation: More than 25 antiretrovirals (ARV) drugs in six mechanistic classes are Food and Drug Administration (FDA)-approved for treatment of HIV infection. These six classes include the nucleoside/nucleotide reverse transcriptase inhibitors (NIs), non-nucleoside reverse transcriptase inhibitors (NNIs), protease inhibitors (PIs), a fusion inhibitor (FI), a CCR5 antagonist, and integrase strand transfer inhibitors (INSTIs). In addition, two drugs, ritonavir (V or r) and cobicistat (COBI or c) are used solely as pharmacokinetic (PK) enhancers (or boosters) to improve the pharmacokinetic profiles of some ARV drugs (e.g., PIs and the INSTI elvitegravir ).Dolutegravir , Elvitegravir , Raltegravir are integrase strand transfer inhibitors (INSTIs).', 'role': 'assistant'}]